Drug-microbiota interactions: an emerging priority for precision medicine.

Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001).

pubmed: 11325631 doi: 10.1016/S1471-4914(01)01986-4

Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).

pubmed: 9555760 doi: 10.1001/jama.279.15.1200

Pirmohamed, M. et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15–19 (2004).

pubmed: 15231615 pmcid: 443443 doi: 10.1136/bmj.329.7456.15

Feitosa Ramos, S. et al. Adverse drug reactions to anti-infectives in hospitalized children: a multicenter study in Brazil. J. Pediatr. Infect. Dis. Soc. 12, 76–82 (2023).

doi: 10.1093/jpids/piac121

Jiang, H. et al. Adverse drug reactions and correlations with drug-drug interactions: a retrospective study of reports from 2011 to 2020. Front. Pharm. 13, 923939 (2022).

doi: 10.3389/fphar.2022.923939

Zhang, Y. et al. Emergency hospitalizations for adverse drug events in China: clinical pharmacists’ approach to assessment and categorization. Pharmacoepidemiol. Drug Saf. 30, 636–643 (2021).

pubmed: 33630347 doi: 10.1002/pds.5215

Konig, I. R., Fuchs, O., Hansen, G., von Mutius, E. & Kopp, M. V. What is precision medicine? Eur. Respir. J. 50, 1700391 (2017).

pubmed: 29051268 doi: 10.1183/13993003.00391-2017

Ramaswami, R., Bayer, R. & Galea, S. Precision medicine from a public health perspective. Annu. Rev. Public Health 39, 153–168 (2018).

pubmed: 29166244 doi: 10.1146/annurev-publhealth-040617-014158

Prasad, R. B. & Groop, L. Precision medicine in type 2 diabetes. J. Intern. Med. 285, 40–48 (2019).

pubmed: 30403316 doi: 10.1111/joim.12859

Buitelaar, J. et al. Toward precision medicine in ADHD. Front. Behav. Neurosci. 16, 900981 (2022).

pubmed: 35874653 pmcid: 9299434 doi: 10.3389/fnbeh.2022.900981

Ahmed, S., Zhou, Z., Zhou, J. & Chen, S. Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom. Proteom. Bioinforma. 14, 298–313 (2016).

doi: 10.1016/j.gpb.2016.03.008

Clarke, J. D. & Cherrington, N. J. Nonalcoholic steatohepatitis in precision medicine: unraveling the factors that contribute to individual variability. Pharm. Ther. 151, 99–106 (2015).

doi: 10.1016/j.pharmthera.2015.03.005

Zhou, Y., Tremmel, R., Schaeffeler, E., Schwab, M. & Lauschke, V. M. Challenges and opportunities associated with rare-variant pharmacogenomics. Trends Pharm. Sci. 43, 852–865 (2022).

pubmed: 36008164 doi: 10.1016/j.tips.2022.07.002

Chang, W. C., Tanoshima, R., Ross, C. J. D. & Carleton, B. C. Challenges and opportunities in implementing pharmacogenetic testing in clinical settings. Annu. Rev. Pharm. Toxicol. 61, 65–84 (2021).

doi: 10.1146/annurev-pharmtox-030920-025745

Johnson, J. A. & Cavallari, L. H. Pharmacogenetics and cardiovascular disease-implications for personalized medicine. Pharm. Rev. 65, 987–1009 (2013).

pubmed: 23686351 pmcid: 3698938 doi: 10.1124/pr.112.007252

Limdi, N. A. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827–3834 (2010).

pubmed: 20203262 pmcid: 2865873 doi: 10.1182/blood-2009-12-255992

Davies, S. M. et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 111, 2984–2990 (2008).

pubmed: 18182569 pmcid: 2265447 doi: 10.1182/blood-2007-09-114082

Roses, A. D. Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 7, 807–817 (2008).

pubmed: 18806753 doi: 10.1038/nrd2593

Swen, J. J. et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401, 347–356 (2023).

pubmed: 36739136 doi: 10.1016/S0140-6736(22)01841-4

Haidar, C. E., Crews, K. R., Hoffman, J. M., Relling, M. V. & Caudle, K. E. Advancing pharmacogenomics from single-gene to preemptive testing. Annu Rev. Genom. Hum. Genet 23, 449–473 (2022).

doi: 10.1146/annurev-genom-111621-102737

Lavertu, A. et al. Pharmacogenomics and big genomic data: from lab to clinic and back again. Hum. Mol. Genet 27, R72–R78 (2018).

pubmed: 29635477 pmcid: 5946941 doi: 10.1093/hmg/ddy116

Weinshilboum, R. M. & Wang, L. Pharmacogenomics: precision medicine and drug response. Mayo Clin. Proc. 92, 1711–1722 (2017).

pubmed: 29101939 doi: 10.1016/j.mayocp.2017.09.001

Roden, D. M. et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145, 749–757 (2006).

pubmed: 17116919 pmcid: 5006954 doi: 10.7326/0003-4819-145-10-200611210-00007

Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137 (2006).

pubmed: 16409140 doi: 10.1146/annurev.med.56.082103.104724

Evans, W. E. & Johnson, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev. Genom. Hum. Genet 2, 9–39 (2001).

doi: 10.1146/annurev.genom.2.1.9

Pirmohamed, M. Pharmacogenomics: current status and future perspectives. Nat. Rev. Genet 24, 350–362 (2023).

pubmed: 36707729 doi: 10.1038/s41576-022-00572-8

Kalow, W., Tang, B. K. & Endrenyi, L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283–289 (1998).

pubmed: 9731714 doi: 10.1097/00008571-199808000-00001

Lindell, A. E., Zimmermann-Kogadeeva, M. & Patil, K. R. Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota. Nat. Rev. Microbiol. 20, 431–443 (2022).

pubmed: 35102308 doi: 10.1038/s41579-022-00681-5

Nie, P. et al. Gut microbiome interventions in human health and diseases. Med. Res. Rev. 39, 2286–2313 (2019).

pubmed: 30994937 doi: 10.1002/med.21584

Hou, K. et al. Microbiota in health and diseases. Signal Transduct. Target Ther. 7, 135 (2022).

pubmed: 35461318 pmcid: 9034083 doi: 10.1038/s41392-022-00974-4

Steiner, H. E. et al. Role of the gut microbiome in cardiovascular drug response: the potential for clinical application. Pharmacotherapy 42, 165–176 (2022).

pubmed: 34820870 doi: 10.1002/phar.2650

Zhou, C. B., Zhou, Y. L. & Fang, J. Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer 7, 647–660 (2021).

pubmed: 33674230 doi: 10.1016/j.trecan.2021.01.010

Roviello, G., Iannone, L. F., Bersanelli, M., Mini, E. & Catalano, M. The gut microbiome and efficacy of cancer immunotherapy. Pharm. Ther. 231, 107973 (2022).

doi: 10.1016/j.pharmthera.2021.107973

Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022).

pubmed: 35228751 pmcid: 8938272 doi: 10.1038/s41591-022-01695-5

Scepanovic, P. et al. A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals. Microbiome 7, 130 (2019).

pubmed: 31519223 pmcid: 6744716 doi: 10.1186/s40168-019-0747-x

Zheng, P. et al. Gut microbial signatures can discriminate unipolar from bipolar depression. Adv. Sci. (Weinh.) 7, 1902862 (2020).

pubmed: 32274300

Vinje, S., Stroes, E., Nieuwdorp, M. & Hazen, S. L. The gut microbiome as novel cardio-metabolic target: the time has come! Eur. Heart J. 35, 883–887 (2014).

pubmed: 24216389 doi: 10.1093/eurheartj/eht467

Wei, M. Y. et al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol. Cancer 18, 97 (2019).

pubmed: 31109338 pmcid: 6526613 doi: 10.1186/s12943-019-1008-0

Robertson, R. C. et al. Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota. Microbiome 6, 95 (2018).

pubmed: 29793531 pmcid: 5968592 doi: 10.1186/s40168-018-0476-6

Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355–1359 (2006).

pubmed: 16741115 pmcid: 3027896 doi: 10.1126/science.1124234

Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).

pubmed: 20203603 pmcid: 3779803 doi: 10.1038/nature08821

Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462–467 (2019).

pubmed: 31158845 pmcid: 6597290 doi: 10.1038/s41586-019-1291-3

Penalver Bernabe, B., Cralle, L. & Gilbert, J. A. Systems biology of the human microbiome. Curr. Opin. Biotechnol. 51, 146–153 (2018).

pubmed: 29453029 doi: 10.1016/j.copbio.2018.01.018

Enright, E. F., Gahan, C. G., Joyce, S. A. & Griffin, B. T. The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382 (2016).

pubmed: 27698621 pmcid: 5045146

Kinross, J. M., Darzi, A. W. & Nicholson, J. K. Gut microbiome-host interactions in health and disease. Genome Med. 3, 14 (2011).

pubmed: 21392406 pmcid: 3092099 doi: 10.1186/gm228

Rodriguez, J. M. et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Micro. Ecol. Health Dis. 26, 26050 (2015).

Piazzon, M. C. et al. Under control: how a dietary additive can restore the gut microbiome and proteomic profile, and improve disease resilience in a marine teleostean fish fed vegetable diets. Microbiome 5, 164 (2017).

pubmed: 29282153 pmcid: 5745981 doi: 10.1186/s40168-017-0390-3

Shkoporov, A. N. et al. Reproducible protocols for metagenomic analysis of human faecal phageomes. Microbiome 6, 68 (2018).

pubmed: 29631623 pmcid: 5892011 doi: 10.1186/s40168-018-0446-z

Montassier, E. et al. CLOUD: a non-parametric detection test for microbiome outliers. Microbiome 6, 137 (2018).

pubmed: 30081949 pmcid: 6080375 doi: 10.1186/s40168-018-0514-4

Huang, L. et al. Analysis of microbiota in elderly patients with Acute Cerebral Infarction. PeerJ 7, e6928 (2019).

pubmed: 31223522 pmcid: 6571007 doi: 10.7717/peerj.6928

Jiang, H. et al. Impact of host intraspecies genetic variation, diet, and age on bacterial and fungal intestinal microbiota in tigers. Microbiologyopen 9, e1050 (2020).

pubmed: 32395912 pmcid: 7349146 doi: 10.1002/mbo3.1050

Visconti, A. et al. Interplay between the human gut microbiome and host metabolism. Nat. Commun. 10, 4505 (2019).

pubmed: 31582752 pmcid: 6776654 doi: 10.1038/s41467-019-12476-z

Chua, L. L. et al. Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation. Microbiome 5, 35 (2017).

pubmed: 28320465 pmcid: 5359958 doi: 10.1186/s40168-017-0250-1

Jackson, M. A. et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat. Commun. 9, 2655 (2018).

pubmed: 29985401 pmcid: 6037668 doi: 10.1038/s41467-018-05184-7

Heirali, A. A. et al. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome 5, 51 (2017).

pubmed: 28476135 pmcid: 5420135 doi: 10.1186/s40168-017-0265-7

Javdan, B. et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell 181, 1661–1679.e22 (2020).

pubmed: 32526207 pmcid: 8591631 doi: 10.1016/j.cell.2020.05.001

Weersma, R. K., Zhernakova, A. & Fu, J. Interaction between drugs and the gut microbiome. Gut 69, 1510–1519 (2020).

pubmed: 32409589 doi: 10.1136/gutjnl-2019-320204

Alexander, J. L. et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 14, 356–365 (2017).

pubmed: 28270698 doi: 10.1038/nrgastro.2017.20

Saad, R., Rizkallah, M. R. & Aziz, R. K. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 4, 16 (2012).

pubmed: 23194438 pmcid: 3529681 doi: 10.1186/1757-4749-4-16

Scher, J. U., Nayak, R. R., Ubeda, C., Turnbaugh, P. J. & Abramson, S. B. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nat. Rev. Rheumatol. 16, 282–292 (2020).

pubmed: 32157196 doi: 10.1038/s41584-020-0395-3

Ting, N. L., Lau, H. C. & Yu, J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71, 1412–1425 (2022).

pubmed: 35277453 doi: 10.1136/gutjnl-2021-326264

Panebianco, C., Andriulli, A. & Pazienza, V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6, 92 (2018).

pubmed: 29789015 pmcid: 5964925 doi: 10.1186/s40168-018-0483-7

Doestzada, M. et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 9, 432–445 (2018).

pubmed: 29705929 pmcid: 5960471 doi: 10.1007/s13238-018-0547-2

Hassan, R. et al. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Brief. Bioinform 22, bbaa292 (2021).

pubmed: 33253350 doi: 10.1093/bib/bbaa292

Sharma, A., Buschmann, M. M. & Gilbert, J. A. Pharmacomicrobiomics: the holy grail to variability in drug response? Clin. Pharm. Ther. 106, 317–328 (2019).

doi: 10.1002/cpt.1437

Tsunoda, S. M., Gonzales, C., Jarmusch, A. K., Momper, J. D. & Ma, J. D. Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability. Clin. Pharmacokinet. 60, 971–984 (2021).

pubmed: 33959897 pmcid: 8332605 doi: 10.1007/s40262-021-01032-y

Lee, H. L. et al. Targeted approaches for in situ gut microbiome manipulation. Genes (Basel) 9, 351 (2018).

pubmed: 30002345 doi: 10.3390/genes9070351

Wong, W. F. & Santiago, M. Microbial approaches for targeting antibiotic-resistant bacteria. Micro. Biotechnol. 10, 1047–1053 (2017).

doi: 10.1111/1751-7915.12783

El Rouby, N., Lima, J. J. & Johnson, J. A. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol. 14, 447–460 (2018).

pubmed: 29620484 pmcid: 5942154 doi: 10.1080/17425255.2018.1461835

Hauser, A. S. et al. Pharmacogenomics of GPCR drug targets. Cell 172, 41–54 e19 (2018).

pubmed: 29249361 pmcid: 5766829 doi: 10.1016/j.cell.2017.11.033

Chaudhry, S. R. et al. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms. Curr. Drug Metab. 15, 711–718 (2014).

pubmed: 25429673 doi: 10.2174/1389200215666141125121952

Muszkat, M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin. Pharm. Ther. 82, 215–218 (2007).

doi: 10.1038/sj.clpt.6100142

Kamath, A. et al. Role of drug transporters in elucidating inter-individual variability in pediatric chemotherapy-related toxicities and response. Pharmaceuticals 15, 990 (2022).

pubmed: 36015138 pmcid: 9415926 doi: 10.3390/ph15080990

Joharatnam-Hogan, N., Shiu, K. K. & Khan, K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat. Rev. 85, 101980 (2020).

pubmed: 32065879 doi: 10.1016/j.ctrv.2020.101980

Murgo, A. J. & Espinoza-Delgado, I. Development of novel anticancer agents in older patients: pharmacokinetic, pharmacodynamic, and other considerations. Cancer J. 11, 481–487 (2005).

pubmed: 16393482 doi: 10.1097/00130404-200511000-00007

Schwartz, J. B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharm. Ther. 82, 87–96 (2007).

doi: 10.1038/sj.clpt.6100226

Deneer, V. H. & van Hemel, N. M. Is antiarrhythmic treatment in the elderly different? a review of the specific changes. Drugs Aging 28, 617–633 (2011).

pubmed: 21812498 doi: 10.2165/11591680-000000000-00000

Besir, F. H. et al. Enoxaparin-associated giant retroperitoneal hematoma in pulmonary embolism treatment. N. Am. J. Med. Sci. 3, 524–526 (2011).

pubmed: 22361501 pmcid: 3271411 doi: 10.4297/najms.2011.3524

Spirk, D. et al. Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Eur. Heart J. 33, 921–926 (2012).

pubmed: 22036872 doi: 10.1093/eurheartj/ehr392

Saltalamacchia, G., Frascaroli, M., Bernardo, A. & Quaquarini, E. Renal and cardiovascular toxicities by new systemic treatments for prostate cancer. Cancers (Basel) 12, 1750 (2020).

pubmed: 32630204 doi: 10.3390/cancers12071750

Masnoon, N., Shakib, S., Kalisch-Ellett, L. & Caughey, G. E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 17, 230 (2017).

pubmed: 29017448 pmcid: 5635569 doi: 10.1186/s12877-017-0621-2

Scherholz, M. L., Rao, R. T. & Androulakis, I. P. Modeling inter-sex and inter-individual variability in response to chronopharmacological administration of synthetic glucocorticoids. Chronobiol. Int. 37, 281–296 (2020).

pubmed: 31797700 doi: 10.1080/07420528.2019.1660357

Conforti, F. et al. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. ESMO Open 6, 100251 (2021).

pubmed: 34455288 pmcid: 8403740 doi: 10.1016/j.esmoop.2021.100251

Federman, D. D. The biology of human sex differences. N. Engl. J. Med. 354, 1507–1514 (2006).

pubmed: 16598047 doi: 10.1056/NEJMra052529

Soldin, O. P. & Mattison, D. R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48, 143–157 (2009).

pubmed: 19385708 pmcid: 3644551 doi: 10.2165/00003088-200948030-00001

Scandlyn, M. J., Stuart, E. C. & Rosengren, R. J. Sex-specific differences in CYP450 isoforms in humans. Expert Opin. Drug Metab. Toxicol. 4, 413–424 (2008).

pubmed: 18524030 doi: 10.1517/17425255.4.4.413

Rodenburg, E. M., Stricker, B. H. & Visser, L. E. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br. J. Clin. Pharm. 71, 95–104 (2011).

doi: 10.1111/j.1365-2125.2010.03811.x

Calcagno, A. et al. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob. Agents Chemother. 57, 1840–1843 (2013).

pubmed: 23380733 pmcid: 3623307 doi: 10.1128/AAC.02434-12

Cerrato, E. et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart 2, e000174 (2015).

pubmed: 25815207 pmcid: 4368980 doi: 10.1136/openhrt-2014-000174

Anderson, G. D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J. Women’s Health (Larchmt.) 14, 19–29 (2005).

doi: 10.1089/jwh.2005.14.19

Anderson, G. D. Gender differences in pharmacological response. Int. Rev. Neurobiol. 83, 1–10 (2008).

pubmed: 18929073 doi: 10.1016/S0074-7742(08)00001-9

Siguret, V., Pautas, E. & Gouin-Thibault, I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam. Horm. 78, 247–264 (2008).

pubmed: 18374198 doi: 10.1016/S0083-6729(07)00012-X

Hirsh, J. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, 8S–21S (2001).

pubmed: 11157640 doi: 10.1378/chest.119.1_suppl.8S

Cavallari, L. H. & Limdi, N. A. Warfarin pharmacogenomics. Curr. Opin. Mol. Ther. 11, 243–251 (2009).

pubmed: 19479657

Park, J. N., Lee, J. S., Noh, M. Y. & Sung, M. K. Association between usual vitamin K intake and anticoagulation in patients under warfarin therapy. Clin. Nutr. Res. 4, 235–241 (2015).

pubmed: 26566518 pmcid: 4641985 doi: 10.7762/cnr.2015.4.4.235

Guaraldi, G. et al. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection 37, 250–255 (2009).

pubmed: 19471855 doi: 10.1007/s15010-008-8025-z

Greenblatt, D. J., Shader, R. I. & Lofgren, S. Rational psycho-pharmacology for patients with medical diseases. Annu Rev. Med. 27, 407–420 (1976).

pubmed: 7180 doi: 10.1146/annurev.me.27.020176.002203

Lv, C., Lv, J., Liu, Y., Liu, Q. & Zou, D. Pediatric pharmaceutical care with anti-infective medication in a patient with acute hematogenous osteomyelitis caused by methicillin-resistant Staphylococcus aureus. Int J. Immunopathol. Pharm. 34, 2058738420925713 (2020).

doi: 10.1177/2058738420925713

Waldinger, R., Weinberg, G. & Gitman, M. Local anesthetic toxicity in the geriatric population. Drugs Aging 37, 1–9 (2020).

pubmed: 31598909 doi: 10.1007/s40266-019-00718-0

Rosmarin, D. M., Lebwohl, M., Elewski, B. E. & Gottlieb, A. B., National Psoriasis, F. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J. Am. Acad. Dermatol. 62, 838–853 (2010).

pubmed: 19932926 doi: 10.1016/j.jaad.2009.05.017

Lewis, J. H. & Stine, J. G. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharm. Ther. 37, 1132–1156 (2013).

doi: 10.1111/apt.12324

Verbeeck, R. K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharm. 64, 1147–1161 (2008).

doi: 10.1007/s00228-008-0553-z

Macpherson, A. J., Heikenwalder, M. & Ganal-Vonarburg, S. C. The liver at the nexus of host-microbial interactions. Cell Host Microbe 20, 561–571 (2016).

pubmed: 27832587 doi: 10.1016/j.chom.2016.10.016

Mani, R. & Pollard, J. R. Antiepileptic drugs and other medications: what interactions may arise? Curr. Treat. Options Neurol. 11, 253–261 (2009).

pubmed: 19523351 doi: 10.1007/s11940-009-0029-1

Huang, L., Lizak, P., Dvorak, C. C., Aweeka, F. & Long-Boyle, J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 960, 194–199 (2014).

doi: 10.1016/j.jchromb.2014.04.045

Relling, M. V. et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285–290 (2000).

pubmed: 11071183 doi: 10.1016/S0140-6736(00)02503-4

Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83–448 (2002).

pubmed: 11996015 doi: 10.1081/DMR-120001392

O’Malley, M., Healy, P., Daignault, S. & Ramnath, N. Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 85, 216–222 (2013).

pubmed: 24080957 doi: 10.1159/000355107

Hamilton, M. et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 12, 2166–2171 (2006).

pubmed: 16609030 doi: 10.1158/1078-0432.CCR-05-2235

Hughes, A. N. et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27, 1220–1226 (2009).

pubmed: 19164205 pmcid: 2667823 doi: 10.1200/JCO.2008.19.3995

van der Bol, J. M. et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 25, 2719–2726 (2007).

pubmed: 17563393 doi: 10.1200/JCO.2006.09.6115

Kanai, M. et al. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann. Oncol. 20, 1397–1401 (2009).

pubmed: 19457938 doi: 10.1093/annonc/mdp008

Dikeocha, I. J., Al-Kabsi, A. M., Miftahussurur, M. & Alshawsh, M. A. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. FASEB J. 36, e22350 (2022).

pubmed: 35579628 doi: 10.1096/fj.202101986R

Enright, E. F., Griffin, B. T., Gahan, C. G. M. & Joyce, S. A. Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. Pharm. Res. 133, 170–186 (2018).

doi: 10.1016/j.phrs.2018.04.009

Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).

pubmed: 31953381 pmcid: 6969170 doi: 10.1038/s41467-019-14177-z

Garrod, A. E. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J. Biol. Med. 75, 221–231 (2002).

pubmed: 12784973 pmcid: 2588790

Perlman, R. L. & Govindaraju, D. R. Archibald E. Garrod: the father of precision medicine. Genet Med. 18, 1088–1089 (2016).

pubmed: 26963281 doi: 10.1038/gim.2016.5

Evans, W. E. & Relling, M. V. Moving towards individualized medicine with pharmacogenomics. Nature 429, 464–468 (2004).

pubmed: 15164072 doi: 10.1038/nature02626

Evans, W. E. & McLeod, H. L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538–549 (2003).

pubmed: 12571262 doi: 10.1056/NEJMra020526

Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529–537 (2003).

pubmed: 12571261 doi: 10.1056/NEJMra020021

Dawed, A. Y. et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 11, 33–41 (2023).

pubmed: 36528349 doi: 10.1016/S2213-8587(22)00340-0

Beutler, E. Drug-induced hemolytic anemia. Pharm. Rev. 21, 73–103 (1969).

pubmed: 4887725

Beutler, E. The hemolytic effect of primaquine and related compounds: a review. Blood 14, 103–139 (1959).

pubmed: 13618370 doi: 10.1182/blood.V14.2.103.103

Beutler, E., Dern, R. J. & Alving, A. S. The hemolytic effect of primaquine. III. A study of primaquine-sensitive erythrocytes. J. Lab Clin. Med. 44, 177–184 (1954).

pubmed: 13184225

Vogel, F. Moderne probleme der humangenetik. Ergebn. Inn. Med. Kinderheilk 12, 52–125 (1959).

Xu, H. et al. Multiplexed SNP genotyping using the Qbead system: a quantum dot-encoded microsphere-based assay. Nucleic Acids Res. 31, e43 (2003).

pubmed: 12682378 pmcid: 153755 doi: 10.1093/nar/gng043

Gibbs, R. A. The Human Genome Project changed everything. Nat. Rev. Genet 21, 575–576 (2020).

pubmed: 32770171 pmcid: 7413016 doi: 10.1038/s41576-020-0275-3

Nebert, D. W., Zhang, G. & Vesell, E. S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40, 187–224 (2008).

pubmed: 18464043 pmcid: 2752627 doi: 10.1080/03602530801952864

Ruiz, C., Zitnik, M. & Leskovec, J. Identification of disease treatment mechanisms through the multiscale interactome. Nat. Commun. 12, 1796 (2021).

pubmed: 33741907 pmcid: 7979814 doi: 10.1038/s41467-021-21770-8

Ming, X. & Laing, B. Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv. Drug Deliv. Rev. 87, 81–89 (2015).

pubmed: 25689735 pmcid: 4504788 doi: 10.1016/j.addr.2015.02.002

Higgins, G. A., Williams, A. M., Ade, A. S., Alam, H. B. & Athey, B. D. Druggable transcriptional networks in the human neurogenic epigenome. Pharm. Rev. 71, 520–538 (2019).

pubmed: 31530573 pmcid: 6750186 doi: 10.1124/pr.119.017681

Varga, J., Dobson, L., Remenyi, I. & Tusnady, G. E. TSTMP: target selection for structural genomics of human transmembrane proteins. Nucleic Acids Res. 45, D325–D330 (2017).

pubmed: 27924015 doi: 10.1093/nar/gkw939

Somogyi, A. A. & Phillips, E. Genomic testing as a tool to optimise drug therapy. Aust. Prescr. 40, 101–104 (2017).

pubmed: 28798515 pmcid: 5478394 doi: 10.18773/austprescr.2017.027

Tam, H. K. et al. Allosteric drug transport mechanism of multidrug transporter AcrB. Nat. Commun. 12, 3889 (2021).

pubmed: 34188038 pmcid: 8242077 doi: 10.1038/s41467-021-24151-3

van de Ven, R. et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 112, 2353–2359 (2008).

pubmed: 18625884 pmcid: 2532808 doi: 10.1182/blood-2008-03-147850

Oslin, D. W. et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial. JAMA 328, 151–161 (2022).

pubmed: 35819423 pmcid: 9277497 doi: 10.1001/jama.2022.9805

Tardif, J. C. et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur. Heart J. 43, 3947–3956 (2022).

pubmed: 35856777 pmcid: 9565632 doi: 10.1093/eurheartj/ehac374

Tsutsumi, K. et al. Structures of the wild-type MexAB-OprM tripartite pump reveal its complex formation and drug efflux mechanism. Nat. Commun. 10, 1520 (2019).

pubmed: 30944318 pmcid: 6447562 doi: 10.1038/s41467-019-09463-9

Nigam, S. K. What do drug transporters really do? Nat. Rev. Drug Discov. 14, 29–44 (2015).

pubmed: 25475361 doi: 10.1038/nrd4461

Surendiran, A., Pradhan, S. C. & Adithan, C. Role of pharmacogenomics in drug discovery and development. Indian J. Pharm. 40, 137–143 (2008).

doi: 10.4103/0253-7613.43158

Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. & Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728–14733 (2009).

pubmed: 19667173 pmcid: 2731842 doi: 10.1073/pnas.0904489106

Zhou, H. H., Koshakji, R. P., Silberstein, D. J., Wilkinson, G. R. & Wood, A. J. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N. Engl. J. Med. 320, 565–570 (1989).

pubmed: 2536896 doi: 10.1056/NEJM198903023200905

Yasuda, S. U., Zhang, L. & Huang, S. M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharm. Ther. 84, 417–423 (2008).

doi: 10.1038/clpt.2008.141

Man, M. et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharm. 50, 929–940 (2010).

doi: 10.1177/0091270009355161

Scharfe, C. P. I., Tremmel, R., Schwab, M., Kohlbacher, O. & Marks, D. S. Genetic variation in human drug-related genes. Genome Med. 9, 117 (2017).

pubmed: 29273096 pmcid: 5740940 doi: 10.1186/s13073-017-0502-5

Bernard, E. et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat. Med. 26, 1549–1556 (2020).

pubmed: 32747829 pmcid: 8381722 doi: 10.1038/s41591-020-1008-z

Taylor, C. A. et al. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 2592–2600 (2022).

pubmed: 36526722 pmcid: 9800275 doi: 10.1038/s41591-022-02095-5

Funnell, T. et al. Single-cell genomic variation induced by mutational processes in cancer. Nature 612, 106–115 (2022).

pubmed: 36289342 pmcid: 9712114 doi: 10.1038/s41586-022-05249-0

Martinez-Ruiz, C. et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature 616, 543–552 (2023).

pubmed: 37046093 pmcid: 10115639 doi: 10.1038/s41586-023-05706-4

Naranbhai, V. et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 23, 172–184 (2022).

pubmed: 34895481 doi: 10.1016/S1470-2045(21)00582-9

Wang, C. W., Preclaro, I. A. C., Lin, W. H. & Chung, W. H. An updated review of genetic associations with severe adverse drug reactions: translation and implementation of pharmacogenomic testing in clinical practice. Front. Pharm. 13, 886377 (2022).

doi: 10.3389/fphar.2022.886377

Khan, D. A., Knowles, S. R. & Shear, N. H. Sulfonamide hypersensitivity: fact and fiction. J. Allergy Clin. Immunol. Pract. 7, 2116–2123 (2019).

pubmed: 31495421 doi: 10.1016/j.jaip.2019.05.034

Chow, T. G. & Khan, D. A. Sulfonamide hypersensitivity. Clin. Rev. Allergy Immunol. 62, 400–412 (2022).

pubmed: 34212341 doi: 10.1007/s12016-021-08872-3

Neuman, M. G. et al. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl. Res. 149, 243–253 (2007).

pubmed: 17466923 doi: 10.1016/j.trsl.2006.12.001

Relman, D. A. & Falkow, S. The meaning and impact of the human genome sequence for microbiology. Trends Microbiol. 9, 206–208 (2001).

pubmed: 11336835 doi: 10.1016/S0966-842X(01)02041-8

Maringanti, V. S., Bucci, V. & Gerber, G. K. MDITRE: scalable and interpretable machine learning for predicting host status from temporal microbiome dynamics. mSystems 7, e0013222 (2022).

pubmed: 36069455 doi: 10.1128/msystems.00132-22

Pflughoeft, K. J. & Versalovic, J. Human microbiome in health and disease. Annu. Rev. Pathol. 7, 99–122 (2012).

pubmed: 21910623 doi: 10.1146/annurev-pathol-011811-132421

Geurtsen, J. et al. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect. Immun. 74, 5574–5585 (2006).

pubmed: 16988232 pmcid: 1594925 doi: 10.1128/IAI.00834-06

ElRakaiby, M. et al. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 18, 402–414 (2014).

pubmed: 24785449 pmcid: 4086029 doi: 10.1089/omi.2014.0018

Gutierrez Lopez, D. E., Lashinger, L. M., Weinstock, G. M. & Bray, M. S. Circadian rhythms and the gut microbiome synchronize the host’s metabolic response to diet. Cell Metab. 33, 873–887 (2021).

pubmed: 33789092 doi: 10.1016/j.cmet.2021.03.015

Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016).

pubmed: 27067014 doi: 10.1038/mp.2016.44

Xue, M. Y., Sun, H. Z., Wu, X. H., Liu, J. X. & Guan, L. L. Multi-omics reveals that the rumen microbiome and its metabolome together with the host metabolome contribute to individualized dairy cow performance. Microbiome 8, 64 (2020).

pubmed: 32398126 pmcid: 7218573 doi: 10.1186/s40168-020-00819-8

Wilson, I. D. & Nicholson, J. K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res. 179, 204–222 (2017).

pubmed: 27591027 doi: 10.1016/j.trsl.2016.08.002

Koppel, N., Maini Rekdal, V. & Balskus, E. P. Chemical transformation of xenobiotics by the human gut microbiota. Science 356, eaag2770 (2017).

pubmed: 28642381 doi: 10.1126/science.aag2770

Khalsa, J., Duffy, L. C., Riscuta, G., Starke-Reed, P. & Hubbard, V. S. Omics for understanding the gut-liver-microbiome axis and precision medicine. Clin. Pharm. Drug Dev. 6, 176–185 (2017).

doi: 10.1002/cpdd.310

Zhao, L. et al. Targeting the human genome-microbiome axis for drug discovery: inspirations from global systems biology and traditional Chinese medicine. J. Proteome Res. 11, 3509–3519 (2012).

pubmed: 22624854 doi: 10.1021/pr3001628

Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968–976 (2019).

pubmed: 31171880 doi: 10.1038/s41591-019-0458-7

Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 568, 499–504 (2019).

pubmed: 30745586 pmcid: 6784870 doi: 10.1038/s41586-019-0965-1

Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet 54, 134–142 (2022).

pubmed: 35115689 pmcid: 9883041 doi: 10.1038/s41588-021-00991-z

Li, Q. et al. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner. Pharm. Res. 170, 105694 (2021).

doi: 10.1016/j.phrs.2021.105694

Kaddurah-Daouk, R. & Weinshilboum, R. Pharmacometabolomics Research Network Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin. Pharm. Ther. 98, 71–75 (2015).

doi: 10.1002/cpt.134

Chakladar, J. et al. The liver microbiome is implicated in cancer prognosis and modulated by alcohol and hepatitis B. Cancers (Basel) 12, 1642 (2020).

pubmed: 32575865 doi: 10.3390/cancers12061642

Grierson, J., Flies, E. J., Bissett, A., Ammitzboll, H. & Jones, P. Which soil microbiome? Bacteria, fungi, and protozoa communities show different relationships with urban green space type and use-intensity. Sci. Total Environ. 863, 160468 (2023).

pubmed: 36464041 doi: 10.1016/j.scitotenv.2022.160468

Wu, X., Xia, Y., He, F., Zhu, C. & Ren, W. Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities. Microbiome 9, 60 (2021).

pubmed: 33715629 pmcid: 7958491 doi: 10.1186/s40168-021-01024-x

Berg, G. et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome 8, 103 (2020).

pubmed: 32605663 pmcid: 7329523 doi: 10.1186/s40168-020-00875-0

El-Sayed, A., Aleya, L. & Kamel, M. Microbiota’s role in health and diseases. Environ. Sci. Pollut. Res. Int. 28, 36967–36983 (2021).

pubmed: 34043164 pmcid: 8155182 doi: 10.1007/s11356-021-14593-z

Marchesi, J. R. & Ravel, J. The vocabulary of microbiome research: a proposal. Microbiome 3, 31 (2015).

pubmed: 26229597 pmcid: 4520061 doi: 10.1186/s40168-015-0094-5

Rajendhran, J. & Gunasekaran, P. Microbial phylogeny and diversity: small subunit ribosomal RNA sequence analysis and beyond. Microbiol. Res. 166, 99–110 (2011).

pubmed: 20223646 doi: 10.1016/j.micres.2010.02.003

Kumar, P. S. Microbiomics: were we all wrong before? Periodontol 2000 85, 8–11 (2021).

pubmed: 33226670 doi: 10.1111/prd.12373

Dominguez-Bello, M. G., Godoy-Vitorino, F., Knight, R. & Blaser, M. J. Role of the microbiome in human development. Gut 68, 1108–1114 (2019).

pubmed: 30670574 doi: 10.1136/gutjnl-2018-317503

Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804–810 (2007).

pubmed: 17943116 pmcid: 3709439 doi: 10.1038/nature06244

Proctor, L. M. The National Institutes of Health Human Microbiome Project. Semin. Fetal Neonatal Med. 21, 368–372 (2016).

pubmed: 27350143 doi: 10.1016/j.siny.2016.05.002

Integrative, H.M.P.R.N.C. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276–289 (2014).

doi: 10.1016/j.chom.2014.08.014

Gilbert, J. A. et al. The Earth Microbiome Project: Meeting report of the “1 EMP meeting on sample selection and acquisition” at Argonne National Laboratory October 6 2010. Stand Genom. Sci. 3, 249–253 (2010).

doi: 10.4056/aigs.1443528

Gilbert, J. A., Jansson, J. K. & Knight, R. The Earth Microbiome project: successes and aspirations. BMC Biol. 12, 69 (2014).

pubmed: 25184604 pmcid: 4141107 doi: 10.1186/s12915-014-0069-1

McCoubrey, L. E., Gaisford, S., Orlu, M. & Basit, A. W. Predicting drug-microbiome interactions with machine learning. Biotechnol. Adv. 54, 107797 (2022).

pubmed: 34260950 doi: 10.1016/j.biotechadv.2021.107797

Pryor, R., Martinez-Martinez, D., Quintaneiro, L. & Cabreiro, F. The role of the microbiome in drug response. Annu. Rev. Pharm. Toxicol. 60, 417–435 (2020).

doi: 10.1146/annurev-pharmtox-010919-023612

Kamath, S., Stringer, A. M., Prestidge, C. A. & Joyce, P. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery. Expert Opin. Drug Deliv. 7, 1–17 (2023).

Becker, H. E. F., Demers, K., Derijks, L. J. J., Jonkers, D. & Penders, J. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Front. Microbiol. 14, 1107976 (2023).

pubmed: 36910207 pmcid: 9996055 doi: 10.3389/fmicb.2023.1107976

Rizkallah, M. R., Saad, R. & Aziz, R. K. The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics. Curr. Pharm. Pers. Med. 8, 182–193 (2010).

Clayton, T. A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073–1077 (2006).

pubmed: 16625200 doi: 10.1038/nature04648

Nicholson, J. K., Wilson, I. D. & Lindon, J. C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12, 103–111 (2011).

pubmed: 21174625 doi: 10.2217/pgs.10.157

Nayak, R. R. & Turnbaugh, P. J. Mirror, mirror on the wall: which microbiomes will help heal them all? BMC Med. 14, 72 (2016).

pubmed: 27146150 pmcid: 4857263 doi: 10.1186/s12916-016-0622-6

Balasopoulou, A., Patrinos, G. P. & Katsila, T. Pharmacometabolomics informs viromics toward precision medicine. Front. Pharm. 7, 411 (2016).

doi: 10.3389/fphar.2016.00411

Katsila, T., Balasopoulou, A., Tsagaraki, I. & Patrinos, G. P. Pharmacomicrobiomics informs clinical pharmacogenomics. Pharmacogenomics 20, 731–739 (2019).

pubmed: 31368841 doi: 10.2217/pgs-2019-0027

Wilson, I. D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl Acad. Sci. USA 106, 14187–14188 (2009).

pubmed: 19706501 pmcid: 2732874 doi: 10.1073/pnas.0907721106

Fu, J. et al. Pharmacometabonomics: data processing and statistical analysis. Brief. Bioinform. 22, bbab138 (2021).

pubmed: 33866355 doi: 10.1093/bib/bbab138

Everett, J. R. From metabonomics to pharmacometabonomics: the role of metabolic profiling in personalized medicine. Front. Pharm. 7, 297 (2016).

doi: 10.3389/fphar.2016.00297

Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. Nat. Rev. Microbiol. 20, 365–380 (2022).

pubmed: 34992261 doi: 10.1038/s41579-021-00667-9

Wainwright, M. & Kristiansen, J. E. On the 75th anniversary of Prontosil. Dyes Pigments 88, 231–234 (2010).

doi: 10.1016/j.dyepig.2010.08.012

Bentley, R. Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams). J. Ind. Microbiol. Biotechnol. 36, 775–786 (2009).

pubmed: 19283418 doi: 10.1007/s10295-009-0553-8

Paranjape, K. et al. Unravelling the importance of the eukaryotic and bacterial communities and their relationship with Legionella spp. ecology in cooling towers: a complex network. Microbiome 8, 157 (2020).

pubmed: 33183356 pmcid: 7664032 doi: 10.1186/s40168-020-00926-6

Lepage, P. et al. A metagenomic insight into our gut’s microbiome. Gut 62, 146–158 (2013).

pubmed: 22525886 doi: 10.1136/gutjnl-2011-301805

Valles-Colomer, M. et al. Meta-omics in inflammatory bowel disease research: applications, challenges, and guidelines. J. Crohns Colitis 10, 735–746 (2016).

pubmed: 26802086 doi: 10.1093/ecco-jcc/jjw024

Sha, G. et al. Integrated meta-omics study on rapid tylosin removal mechanism and dynamics of antibiotic resistance genes during aerobic thermophilic fermentation of tylosin mycelial dregs. Bioresour. Technol. 351, 127010 (2022).

pubmed: 35307520 doi: 10.1016/j.biortech.2022.127010

McDaniel, E. A. et al. Prospects for multi-omics in the microbial ecology of water engineering. Water Res. 205, 117608 (2021).

pubmed: 34555741 doi: 10.1016/j.watres.2021.117608

Kaddurah-Daouk, R. & Weinshilboum, R. M. Pharmacometabolomics Research Network Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin. Pharm. Ther. 95, 154–167 (2014).

doi: 10.1038/clpt.2013.217

Kaddurah-Daouk, R., Kristal, B. S. & Weinshilboum, R. M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharm. Toxicol. 48, 653–683 (2008).

doi: 10.1146/annurev.pharmtox.48.113006.094715

Nicholson, J. K. & Wilson, I. D. Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2, 668–676 (2003).

pubmed: 12904817 doi: 10.1038/nrd1157

Beger, R. D., Schmidt, M. A. & Kaddurah-Daouk, R. Current concepts in pharmacometabolomics, biomarker discovery, and precision medicine. Metabolites 10, 129 (2020).

pubmed: 32230776 pmcid: 7241083 doi: 10.3390/metabo10040129

Everett, J. R., Loo, R. L. & Pullen, F. S. Pharmacometabonomics and personalized medicine. Ann. Clin. Biochem. 50, 523–545 (2013).

pubmed: 23888060 doi: 10.1177/0004563213497929

Everett, J. R. Pharmacometabonomics in humans: a new tool for personalized medicine. Pharmacogenomics 16, 737–754 (2015).

pubmed: 25929853 doi: 10.2217/pgs.15.20

Rosato, A. et al. From correlation to causation: analysis of metabolomics data using systems biology approaches. Metabolomics 14, 37 (2018).

pubmed: 29503602 pmcid: 5829120 doi: 10.1007/s11306-018-1335-y

McWhinney, S. R. & McLeod, H. L. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10, 489–493 (2009).

pubmed: 19650256 doi: 10.2217/14622416.10.3.489

Derosa, L. et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396–2412 (2021).

pubmed: 34400407 doi: 10.1158/2159-8290.CD-21-0236

He, Y., Liu, Q. W., Liao, H. X. & Xu, W. W. Microbiota in cancer chemoradiotherapy resistance. Clin. Transl. Med. 11, e250 (2021).

pubmed: 33463064 doi: 10.1002/ctm2.250

Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638–647 (2009).

pubmed: 19786984 doi: 10.1038/nrclinonc.2009.146

Gershwin, M. E., Goetzl, E. J. & Steinberg, A. D. Cyclophosphamide: use in practice. Ann. Intern. Med. 80, 531–540 (1974).

pubmed: 4621265 doi: 10.7326/0003-4819-80-4-531

Patel, J. M. Metabolism and pulmonary toxicity of cyclophosphamide. Pharm. Ther. 47, 137–146 (1990).

doi: 10.1016/0163-7258(90)90049-8

Barnes, H., Holland, A. E., Westall, G. P., Goh, N. S. & Glaspole, I. N. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst. Rev. 1, CD010908 (2018).

pubmed: 29297205

Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310 (1996).

pubmed: 8608507 doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5

Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

pubmed: 12529460 doi: 10.1056/NEJMoa020177

Katz, S. C. et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann. Surg. Oncol. 16, 2524–2530 (2009).

pubmed: 19568816 doi: 10.1245/s10434-009-0585-3

Jamiyan, T. et al. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. Breast Cancer 27, 880–892 (2020).

pubmed: 32222891 doi: 10.1007/s12282-020-01084-1

Roy, S. & Trinchieri, G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271–285 (2017).

pubmed: 28303904 doi: 10.1038/nrc.2017.13

Viaud, S. et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 71, 661–665 (2011).

pubmed: 21148486 doi: 10.1158/0008-5472.CAN-10-1259

Nakahara, T. et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 115, 4384–4392 (2010).

pubmed: 20154220 pmcid: 2881499 doi: 10.1182/blood-2009-11-251231

Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336–344 (2004).

pubmed: 14768038 doi: 10.1002/eji.200324181

Bracci, L. et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13, 644–653 (2007).

pubmed: 17255288 doi: 10.1158/1078-0432.CCR-06-1209

Sistigu, A. et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33, 369–383 (2011).

pubmed: 21611872 doi: 10.1007/s00281-011-0245-0

Hughes, E. et al. T-cell modulation by cyclophosphamide for tumour therapy. Immunology 154, 62–68 (2018).

pubmed: 29460448 pmcid: 5904691 doi: 10.1111/imm.12913

Madondo, M. T., Quinn, M. & Plebanski, M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat. Rev. 42, 3–9 (2016).

pubmed: 26620820 doi: 10.1016/j.ctrv.2015.11.005

Zhao, C. et al. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. J. Hematol. Oncol. 15, 64 (2022).

pubmed: 35590334 pmcid: 9118756 doi: 10.1186/s13045-022-01287-3

Toulmonde, M., Demolis, P. & Houede, N. Salvage chemotherapy for hormone-refractory prostate cancer: association of Adriamycin and ifosfamide. Exp. Ther. Med. 1, 1005–1011 (2010).

pubmed: 22993633 pmcid: 3445988 doi: 10.3892/etm.2010.138

Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).

pubmed: 24264990 pmcid: 4048947 doi: 10.1126/science.1240537

Yang, J., Liu, K. X., Qu, J. M. & Wang, X. D. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. Eur. J. Pharm. 714, 120–124 (2013).

doi: 10.1016/j.ejphar.2013.06.006

Xu, X. & Zhang, X. Effects of cyclophosphamide on immune system and gut microbiota in mice. Microbiol. Res. 171, 97–106 (2015).

pubmed: 25553830 doi: 10.1016/j.micres.2014.11.002

Daillere, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931–943 (2016).

pubmed: 27717798 doi: 10.1016/j.immuni.2016.09.009

Mego, M. et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther. Med. 23, 356–362 (2015).

pubmed: 26051570 doi: 10.1016/j.ctim.2015.03.008

Bleiberg, H. CPT-11 in gastrointestinal cancer. Eur. J. Cancer 35, 371–379 (1999).

pubmed: 10448285 doi: 10.1016/S0959-8049(98)00423-7

Dobi, A., Gasque, P., Guiraud, P. & Selambarom, J. Irinotecan (CPT-11) canonical anti-cancer drug can also modulate antiviral and pro-inflammatory responses of primary human synovial fibroblasts. Cells 10, 1431 (2021).

pubmed: 34201243 pmcid: 8230279 doi: 10.3390/cells10061431

Bailly, C. Irinotecan: 25 years of cancer treatment. Pharm. Res. 148, 104398 (2019).

doi: 10.1016/j.phrs.2019.104398

Zhao, J. et al. In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy. Biomaterials 268, 120542 (2021).

pubmed: 33249316 doi: 10.1016/j.biomaterials.2020.120542

Karas, S. et al. Optimal sampling strategies for irinotecan (CPT-11) and its active metabolite (SN-38) in cancer patients. AAPS J. 22, 59 (2020).

pubmed: 32185579 doi: 10.1208/s12248-020-0429-4

Stringer, A. M. et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol. Ther. 7, 1919–1925 (2008).

pubmed: 18927500 doi: 10.4161/cbt.7.12.6940

Flieger, D. et al. Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 72, 10–16 (2007).

pubmed: 17998785 doi: 10.1159/000111083

Kehrer, D. F. et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin. Cancer Res. 7, 1136–1141 (2001).

pubmed: 11350876

Leibovici, L. et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107, 1743–1751 (2006).

pubmed: 16977651 doi: 10.1002/cncr.22205

Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).

pubmed: 21051639 pmcid: 3110694 doi: 10.1126/science.1191175

Kong, R. et al. Old drug new use-amoxapine and its metabolites as potent bacterial beta-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin. Cancer Res. 20, 3521–3530 (2014).

pubmed: 24780296 pmcid: 4079752 doi: 10.1158/1078-0432.CCR-14-0395

Huang, P. T. et al. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors. Cancer Gene Ther. 18, 381–389 (2011).

pubmed: 21350582 doi: 10.1038/cgt.2011.3

Cheng, K. W. et al. Pharmacological inhibition of bacterial beta-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharm. Res. 139, 41–49 (2019).

doi: 10.1016/j.phrs.2018.10.029

Chamseddine, A. N. et al. Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharm. Ther. 199, 1–15 (2019).

doi: 10.1016/j.pharmthera.2019.03.002

Gallotti, B. et al. Effects of dietary fibre intake in chemotherapy-induced mucositis in murine model. Br. J. Nutr. 126, 853–864 (2021).

pubmed: 33298215 doi: 10.1017/S0007114520004924

Takasuna, K. et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 3752–3757 (1996).

pubmed: 8706020

Songjang, W. et al. Tumor-promoting activity and proteomic profiling of cisplatin/oxaliplatin-derived DAMPs in cholangiocarcinoma cells. Int J. Mol. Sci. 23, 10540 (2022).

pubmed: 36142453 pmcid: 9502173 doi: 10.3390/ijms231810540

Skripova, V., Vlasenkova, R., Zhou, Y., Astsaturov, I. & Kiyamova, R. Identification of new regulators of pancreatic cancer cell sensitivity to oxaliplatin and cisplatin. Molecules 27, 1289 (2022).

pubmed: 35209078 pmcid: 8875979 doi: 10.3390/molecules27041289

Zhang, C., Xu, C., Gao, X. & Yao, Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12, 2115–2132 (2022).

pubmed: 35265202 pmcid: 8899578 doi: 10.7150/thno.69424

Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann. Oncol. 26, 141–148 (2015).

pubmed: 25316259 doi: 10.1093/annonc/mdu472

Vaisman, A., Masutani, C., Hanaoka, F. & Chaney, S. G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 39, 4575–4580 (2000).

pubmed: 10769112 doi: 10.1021/bi000130k

Cruet-Hennequart, S., Glynn, M. T., Murillo, L. S., Coyne, S. & Carty, M. P. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin. DNA Repair (Amst.) 7, 582–596 (2008).

pubmed: 18289945 doi: 10.1016/j.dnarep.2007.12.012

Lokody, I. Tumour microenvironment: bacterial balance affects cancer treatment. Nat. Rev. Cancer 14, 10 (2014).

pubmed: 24505616 doi: 10.1038/nrc3827

Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).

pubmed: 24264989 pmcid: 6709532 doi: 10.1126/science.1240527

Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020).

pubmed: 32451498 doi: 10.1038/s41591-020-0882-8

Bachem, A. et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells. Immunity 51, 285–297 e5 (2019).

pubmed: 31272808 doi: 10.1016/j.immuni.2019.06.002

He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 33, 988–1000 e7 (2021).

pubmed: 33761313 doi: 10.1016/j.cmet.2021.03.002

Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).

pubmed: 31690319 pmcid: 6833286 doi: 10.1186/s12943-019-1091-2

Andrews, L. P., Yano, H. & Vignali, D. A. A. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat. Immunol. 20, 1425–1434 (2019).

pubmed: 31611702 doi: 10.1038/s41590-019-0512-0

Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 52, 39–52 (2018).

pubmed: 28987965 doi: 10.1016/j.semcancer.2017.10.001

Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).

pubmed: 26541610 pmcid: 4721659 doi: 10.1126/science.aad1329

Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).

pubmed: 26541606 pmcid: 4873287 doi: 10.1126/science.aac4255

Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368–1379 (2017).

pubmed: 28368458 doi: 10.1093/annonc/mdx108

Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).

pubmed: 29097493 doi: 10.1126/science.aan4236

Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

pubmed: 29097494 doi: 10.1126/science.aan3706

Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

pubmed: 29302014 pmcid: 6707353 doi: 10.1126/science.aao3290

Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).

pubmed: 30675064 doi: 10.1038/s41586-019-0878-z

Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).

pubmed: 31942075 pmcid: 8762581 doi: 10.1038/s41586-019-1922-8

Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567–574 (2020).

pubmed: 32214244 pmcid: 7500457 doi: 10.1038/s41586-020-2095-1

Costea, P. I. et al. Towards standards for human fecal sample processing in metagenomic studies. Nat. Biotechnol. 35, 1069–1076 (2017).

pubmed: 28967887 doi: 10.1038/nbt.3960

Tam, V. et al. Benefits and limitations of genome-wide association studies. Nat. Rev. Genet 20, 467–484 (2019).

pubmed: 31068683 doi: 10.1038/s41576-019-0127-1

Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).

pubmed: 33303685 doi: 10.1126/science.abb5920

Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).

pubmed: 33542131 pmcid: 8097968 doi: 10.1126/science.abf3363

Jamison, D. T. et al. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development/ The World Bank (2006).

Ruan, Y. et al. Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1. BMC Public Health 18, 778 (2018).

pubmed: 29925336 pmcid: 6011508 doi: 10.1186/s12889-018-5653-9

Nitsa, A. et al. Vitamin D in cardiovascular disease. Vivo 32, 977–981 (2018).

doi: 10.21873/invivo.11338

Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017).

pubmed: 28527533 pmcid: 5491406 doi: 10.1016/j.jacc.2017.04.052

Zuo, H. L. et al. Interactions of antithrombotic herbal medicines with Western cardiovascular drugs. Pharm. Res. 159, 104963 (2020).

doi: 10.1016/j.phrs.2020.104963

Curini, L. & Amedei, A. Cardiovascular diseases and pharmacomicrobiomics: a perspective on possible treatment relevance. Biomedicines 9, 1338 (2021).

pubmed: 34680455 pmcid: 8533057 doi: 10.3390/biomedicines9101338

Kyoung, J., Atluri, R. R. & Yang, T. Resistance to antihypertensive drugs: is gut microbiota the missing link? Hypertension 79, 2138–2147 (2022).

pubmed: 35862173 doi: 10.1161/HYPERTENSIONAHA.122.19826

Chakaroun, R. M., Olsson, L. M. & Backhed, F. The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease. Nat. Rev. Cardiol. 20, 217–235 (2023).

pubmed: 36241728 doi: 10.1038/s41569-022-00771-0

Yang, Z. et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clin. Exp. Hypertens. 45, 2195135 (2023).

pubmed: 36994745 doi: 10.1080/10641963.2023.2195135

Chen, H. Q. et al. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front. Med. (Lausanne) 8, 742394 (2021).

pubmed: 35127738 doi: 10.3389/fmed.2021.742394

Pirmohamed, M. Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharm. 62, 509–511 (2006).

doi: 10.1111/j.1365-2125.2006.02806.x

Kimmel, S. E. Warfarin pharmacogenomics: current best evidence. J. Thromb. Haemost. 13, S266–S271 (2015).

pubmed: 26149035 doi: 10.1111/jth.12978

Wu, S. et al. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. Blood 132, 647–657 (2018).

pubmed: 29743176 pmcid: 6085993 doi: 10.1182/blood-2018-01-830901

Czogalla, K. J. et al. Warfarin and vitamin K compete for binding to Phe55 in human VKOR. Nat. Struct. Mol. Biol. 24, 77–85 (2017).

pubmed: 27941861 doi: 10.1038/nsmb.3338

Chen, X. et al. A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase. J. Thromb. Haemost. 19, 689–700 (2021).

pubmed: 33314621 pmcid: 7925372 doi: 10.1111/jth.15209

Rishavy, M. A. et al. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. Blood 131, 2826–2835 (2018).

pubmed: 29592891 pmcid: 6014353 doi: 10.1182/blood-2017-09-804666

Wise, E. S. et al. The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty. J. Orthop. 12, S145–S151 (2015).

pubmed: 27047214 pmcid: 4796661 doi: 10.1016/j.jor.2015.10.023

Jorgensen, A. L., FitzGerald, R. J., Oyee, J., Pirmohamed, M. & Williamson, P. R. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7, e44064 (2012).

pubmed: 22952875 pmcid: 3430615 doi: 10.1371/journal.pone.0044064

Xue, L. et al. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. Br. J. Clin. Pharm. 83, 823–835 (2017).

doi: 10.1111/bcp.13157

Wang, L. et al. The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin. Pharm. Res. 159, 104979 (2020).

doi: 10.1016/j.phrs.2020.104979

Ward, N. C., Watts, G. F. & Eckel, R. H. Statin toxicity. Circ. Res. 124, 328–350 (2019).

pubmed: 30653440 doi: 10.1161/CIRCRESAHA.118.312782

Lim, G. B. Statins outperform dietary supplements for LDL-C lowering. Nat. Rev. Cardiol. 20, 6 (2023).

pubmed: 36376436

Dehnavi, S. et al. Statins and autoimmunity: state-of-the-art. Pharm. Ther. 214, 107614 (2020).

doi: 10.1016/j.pharmthera.2020.107614

Arnett, D. K. et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596–e646 (2019).

pubmed: 30879355 pmcid: 7734661

Zhou, Q. & Liao, J. K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des. 15, 467–478 (2009).

pubmed: 19199975 pmcid: 2896785 doi: 10.2174/138161209787315684

Oesterle, A., Laufs, U. & Liao, J. K. Pleiotropic effects of statins on the cardiovascular system. Circ. Res. 120, 229–243 (2017).

pubmed: 28057795 pmcid: 5467317 doi: 10.1161/CIRCRESAHA.116.308537

Kim, J. et al. Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia. Front. Microbiol. 10, 1947 (2019).

pubmed: 31551944 pmcid: 6736992 doi: 10.3389/fmicb.2019.01947

Caparros-Martin, J. A. et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5, 95 (2017).

pubmed: 28793934 pmcid: 5550934 doi: 10.1186/s40168-017-0312-4

Tuteja, S. & Ferguson, J. F. Gut microbiome and response to cardiovascular drugs. Circ. Genom. Precis Med. 12, 421–429 (2019).

pubmed: 31462078 pmcid: 6751004 doi: 10.1161/CIRCGEN.119.002314

Campbell, T. J. & MacDonald, P. S. Digoxin in heart failure and cardiac arrhythmias. Med. J. Aust. 179, 98–102 (2003).

pubmed: 12864722 doi: 10.5694/j.1326-5377.2003.tb05445.x

Patocka, J., Nepovimova, E., Wu, W. & Kuca, K. Digoxin: pharmacology and toxicology-A review. Environ. Toxicol. Pharm. 79, 103400 (2020).

doi: 10.1016/j.etap.2020.103400

Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298 (2013).

pubmed: 23869020 pmcid: 3736355 doi: 10.1126/science.1235872

Saha, J. R., Butler, V. P. Jr, Neu, H. C. & Lindenbaum, J. Digoxin-inactivating bacteria: identification in human gut flora. Science 220, 325–327 (1983).

pubmed: 6836275 doi: 10.1126/science.6836275

Bo, J. et al. Eggerthella lenta bloodstream infections: two cases and review of the literature. Future Microbiol. 15, 981–985 (2020).

pubmed: 32815419 doi: 10.2217/fmb-2019-0338

Kageyama, A., Benno, Y. & Nakase, T. Phylogenetic evidence for the transfer of Eubacterium lentum to the genus Eggerthella as Eggerthella lenta gen. nov., comb. nov. Int J. Syst. Bacteriol. 49, 1725–1732 (1999).

pubmed: 10555354 doi: 10.1099/00207713-49-4-1725

Haiser, H. J., Seim, K. L., Balskus, E. P. & Turnbaugh, P. J. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 5, 233–238 (2014).

pubmed: 24637603 pmcid: 4063850 doi: 10.4161/gmic.27915

David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).

pubmed: 24336217 doi: 10.1038/nature12820

Evered, M. D., Robinson, M. M. & Richardson, M. A. Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain. Eur. J. Pharm. 68, 443–449 (1980).

doi: 10.1016/0014-2999(80)90419-7

Antunes, A. M., Guerrante, R. D., Avila, J. P., Lins Mendes, F. M. & Fierro, I. M. Case study of patents related to captopril, Squibb’s first blockbuster. Expert Opin. Ther. Pat. 26, 1449–1457 (2016).

pubmed: 27573807 doi: 10.1080/13543776.2016.1227321

Berecek, K. H., Reaves, P. & Raizada, M. Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats. Vasc. Pharm. 42, 93–98 (2005).

doi: 10.1016/j.vph.2005.01.010

Wu, J. N. & Berecek, K. H. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 22, 139–146 (1993).

pubmed: 8340149 doi: 10.1161/01.HYP.22.2.139

Zhang, L., Edwards, D. G. & Berecek, K. H. Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin. Exp. Hypertens. 18, 201–226 (1996).

pubmed: 8869001 doi: 10.3109/10641969609081765

Wu, H., Lam, T. Y. C., Shum, T. F., Tsai, T. Y. & Chiou, J. Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration. Hypertens. Res. 45, 270–282 (2022).

pubmed: 34857899 doi: 10.1038/s41440-021-00796-x

Yang, T. et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat. J. Am. Heart Assoc. 8, e010721 (2019).

pubmed: 30755073 pmcid: 6405665 doi: 10.1161/JAHA.118.010721

Yang, T., Richards, E. M., Pepine, C. J. & Raizada, M. K. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat. Rev. Nephrol. 14, 442–456 (2018).

pubmed: 29760448 pmcid: 6385605 doi: 10.1038/s41581-018-0018-2

Santisteban, M. M., Kim, S., Pepine, C. J. & Raizada, M. K. Brain-gut-bone marrow axis: implications for hypertension and related therapeutics. Circ. Res. 118, 1327–1336 (2016).

pubmed: 27081113 pmcid: 4834860 doi: 10.1161/CIRCRESAHA.116.307709

Li, H. B., Yang, T., Richards, E. M., Pepine, C. J. & Raizada, M. K. Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring. Hypertension 75, 1315–1324 (2020).

pubmed: 32200676 doi: 10.1161/HYPERTENSIONAHA.120.14736

Qi, Y., Aranda, J. M., Rodriguez, V., Raizada, M. K. & Pepine, C. J. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension—a case report. Int J. Cardiol. 201, 157–158 (2015).

pubmed: 26301638 pmcid: 4711349 doi: 10.1016/j.ijcard.2015.07.078

Angiotensin-Converting Enzyme Inhibitors. in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Bethesda, 2012).

Wang, B. L., Pan, D. Q., Zhou, K. L., Lou, Y. Y. & Shi, J. H. Multi-spectroscopic approaches and molecular simulation research of the intermolecular interaction between the angiotensin-converting enzyme inhibitor (ACE inhibitor) benazepril and bovine serum albumin (BSA). Spectrochim. Acta A Mol. Biomol. Spectrosc. 212, 15–24 (2019).

pubmed: 30594849 doi: 10.1016/j.saa.2018.12.040

Hou, F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131–140 (2006).

pubmed: 16407508 doi: 10.1056/NEJMoa053107

Senthong, V. et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J. Am. Heart Assoc. 5, e002816 (2016).

pubmed: 27287696 pmcid: 4937244 doi: 10.1161/JAHA.115.002816

Li, X. S. et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur. Heart J. 38, 814–824 (2017).

pubmed: 28077467 pmcid: 5837488

Tang, W. H. et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin. Chem. 63, 297–306 (2017).

pubmed: 27864387 doi: 10.1373/clinchem.2016.263640

Konop, M. et al. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. Biomarkers 23, 380–385 (2018).

pubmed: 29363331 doi: 10.1080/1354750X.2018.1432689

Romano, K. A., Vivas, E. I., Amador-Noguez, D. & Rey, F. E. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 6, e02481 (2015).

pubmed: 25784704 pmcid: 4453578 doi: 10.1128/mBio.02481-14

Craciun, S. & Balskus, E. P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl Acad. Sci. USA 109, 21307–21312 (2012).

pubmed: 23151509 pmcid: 3535645 doi: 10.1073/pnas.1215689109

Nowinski, A. & Ufnal, M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases? Nutrition 46, 7–12 (2018).

pubmed: 29290360 doi: 10.1016/j.nut.2017.08.001

Jaworska, K. et al. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS One 12, e0189310 (2017).

pubmed: 29236735 pmcid: 5728578 doi: 10.1371/journal.pone.0189310

Qi, X., Yun, C., Pang, Y. & Qiao, J. The impact of the gut microbiota on the reproductive and metabolic endocrine system. Gut Microbes 13, 1–21 (2021).

pubmed: 33722164 doi: 10.1080/19490976.2021.1894070

Cornejo-Pareja, I., Munoz-Garach, A., Clemente-Postigo, M. & Tinahones, F. J. Importance of gut microbiota in obesity. Eur. J. Clin. Nutr. 72, 26–37 (2019).

pubmed: 30487562 doi: 10.1038/s41430-018-0306-8

Pascale, A. et al. Microbiota and metabolic diseases. Endocrine 61, 357–371 (2018).

pubmed: 29721802 doi: 10.1007/s12020-018-1605-5

Neuman, H., Debelius, J. W., Knight, R. & Koren, O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol. Rev. 39, 509–521 (2015).

pubmed: 25701044 doi: 10.1093/femsre/fuu010

Han, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 18, 96 (2019).

pubmed: 31362743 pmcid: 6668189 doi: 10.1186/s12933-019-0900-7

LaMoia, T. E. & Shulman, G. I. Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42, 77–96 (2021).

pubmed: 32897388 doi: 10.1210/endrev/bnaa023

Giusti, L. et al. The protective action of metformin against pro-inflammatory cytokine-induced human islet cell damage and the mechanisms involved. Cells 11, 2465 (2022).

pubmed: 35954309 pmcid: 9368307 doi: 10.3390/cells11152465

Sundelin, E., Jensen, J. B., Jakobsen, S., Gormsen, L. C. & Jessen, N. Metformin biodistribution: a key to mechanisms of action? J. Clin. Endocrinol. Metab. 105, dgaa332 (2020).

pubmed: 32480406 doi: 10.1210/clinem/dgaa332

Minamii, T., Nogami, M. & Ogawa, W. Mechanisms of metformin action: in and out of the gut. J. Diabetes Investig. 9, 701–703 (2018).

pubmed: 29777629 pmcid: 6031513 doi: 10.1111/jdi.12864

Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of metformin. Diabetologia 60, 1577–1585 (2017).

pubmed: 28776086 pmcid: 5552828 doi: 10.1007/s00125-017-4342-z

Foretz, M., Guigas, B. & Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 15, 569–589 (2019).

pubmed: 31439934 doi: 10.1038/s41574-019-0242-2

Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017).

pubmed: 28530702 doi: 10.1038/nm.4345

Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919–1929 (2018).

pubmed: 30397356 pmcid: 6479226 doi: 10.1038/s41591-018-0222-4

Bryrup, T. et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia 62, 1024–1035 (2019).

pubmed: 30904939 pmcid: 6509092 doi: 10.1007/s00125-019-4848-7

Pollak, M. The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia 60, 1662–1667 (2017).

pubmed: 28770326 doi: 10.1007/s00125-017-4352-x

Duca, F. A. et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat. Med. 21, 506–511 (2015).

pubmed: 25849133 pmcid: 6104807 doi: 10.1038/nm.3787

Luo, F. et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc. Diabetol. 18, 54 (2019).

pubmed: 31029144 pmcid: 6486984 doi: 10.1186/s12933-019-0860-y

Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478 (2019).

pubmed: 31123355 doi: 10.1038/s41575-019-0157-3

Agrawal, N., Sharma, M., Singh, S. & Goyal, A. Recent advances of alpha-glucosidase inhibitors: a comprehensive review. Curr. Top. Med. Chem. 22, 2069–2086 (2022).

pubmed: 36045528 doi: 10.2174/1568026622666220831092855

Dhameja, M. & Gupta, P. Synthetic heterocyclic candidates as promising alpha-glucosidase inhibitors: an overview. Eur. J. Med. Chem. 176, 343–377 (2019).

pubmed: 31112894 doi: 10.1016/j.ejmech.2019.04.025

Zhang, X. et al. Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial. Diabetes Ther. 8, 293–307 (2017).

pubmed: 28130771 pmcid: 5380489 doi: 10.1007/s13300-017-0226-y

Brunkhorst, C., Andersen, C. & Schneider, E. Acarbose, a pseudooligosaccharide, is transported but not metabolized by the maltose-maltodextrin system of Escherichia coli. J. Bacteriol. 181, 2612–2619 (1999).

pubmed: 10198028 pmcid: 93690 doi: 10.1128/JB.181.8.2612-2619.1999

Yadav, H., Jain, S. & Sinha, P. R. Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats. Biosci. Biotechnol. Biochem. 70, 1255–1258 (2006).

pubmed: 16717431 doi: 10.1271/bbb.70.1255

Yadav, H., Jain, S. & Sinha, P. R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 23, 62–68 (2007).

pubmed: 17084593 doi: 10.1016/j.nut.2006.09.002

Kaushal, D. & Kansal, V. K. Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum improves phagocytic potential of macrophages in aged mice. J. Food Sci. Technol. 51, 1147–1153 (2014).

pubmed: 24876648 doi: 10.1007/s13197-012-0637-8

Su, B. et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J. Diabetes 7, 729–739 (2015).

pubmed: 25327485 doi: 10.1111/1753-0407.12232

Maruhama, Y. et al. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohoku J. Exp. Med. 132, 453–462 (1980).

pubmed: 7256727 doi: 10.1620/tjem.132.453

Kishida, Y., Okubo, H., Ohno, H., Oki, K. & Yoneda, M. Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. J. Gastroenterol. 52, 1180–1191 (2017).

pubmed: 28349245 pmcid: 5666045 doi: 10.1007/s00535-017-1331-4

Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705 (2006).

pubmed: 17098089 doi: 10.1016/S0140-6736(06)69705-5

Meier, J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728–742 (2012).

pubmed: 22945360 doi: 10.1038/nrendo.2012.140

Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).

pubmed: 29617641 doi: 10.1016/j.cmet.2018.03.001

Baggio, L. L. & Drucker, D. J. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J. Clin. Invest. 124, 4223–4226 (2014).

pubmed: 25202976 pmcid: 4191040 doi: 10.1172/JCI78371

Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371 (2012).

pubmed: 22190648 pmcid: 3266401 doi: 10.2337/db11-1019

Kimura, I. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 4, 1829 (2013).

pubmed: 23652017 doi: 10.1038/ncomms2852

Vettorazzi, J. F. et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism 65, 54–63 (2016).

pubmed: 26892516 doi: 10.1016/j.metabol.2015.10.021

Aoki, R. et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci. Rep. 7, 43522 (2017).

pubmed: 28252037 pmcid: 5333160 doi: 10.1038/srep43522

Wang, L., Li, P., Tang, Z., Yan, X. & Feng, B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci. Rep. 6, 33251 (2016).

pubmed: 27633081 pmcid: 5025740 doi: 10.1038/srep33251

Zhang, Q. et al. Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp. Biol. Med. (Maywood) 243, 34–44 (2018).

pubmed: 29171288 doi: 10.1177/1535370217743765

Zhao, L. et al. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front. Endocrinol. (Lausanne) 9, 233 (2018).

pubmed: 29867765 doi: 10.3389/fendo.2018.00233

Charpentier, J. et al. Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion. Acta Diabetol. 58, 881–897 (2021).

pubmed: 33723651 doi: 10.1007/s00592-020-01657-8

Shang, J. et al. Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. PeerJ 9, e11128 (2021).

pubmed: 33850659 pmcid: 8019531 doi: 10.7717/peerj.11128

Yuan, X. et al. Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora. J. Cell Biochem. 119, 10067–10074 (2018).

pubmed: 30129059 doi: 10.1002/jcb.27343

Handelsman, Y. et al. American association of clinical endocrinologists and american college of endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr. Pract. 21, 1–87 (2015).

pubmed: 25869408 pmcid: 4959114 doi: 10.4158/EP15672.GLSUPPL

Olivares, M. et al. The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. Front. Microbiol. 9, 1900 (2018).

pubmed: 30186247 pmcid: 6113382 doi: 10.3389/fmicb.2018.01900

Liao, X. et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EBioMedicine 44, 665–674 (2019).

pubmed: 30922964 pmcid: 6603491 doi: 10.1016/j.ebiom.2019.03.057

Yan, X., Feng, B., Li, P., Tang, Z. & Wang, L. Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study. J. Diabetes Res. 2016, 2093171 (2016).

pubmed: 27631013 pmcid: 5007364 doi: 10.1155/2016/2093171

Zhang, Q. et al. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS One 12, e0184735 (2017).

pubmed: 29036231 pmcid: 5643055 doi: 10.1371/journal.pone.0184735

Zhao, X. et al. Host-microbiota interaction-mediated resistance to inflammatory bowel disease in pigs. Microbiome 10, 115 (2022).

pubmed: 35907917 pmcid: 9338544 doi: 10.1186/s40168-022-01303-1

Alshehri, D. et al. Dysbiosis of gut microbiota in inflammatory bowel disease: current therapies and potential for microbiota-modulating therapeutic approaches. Bosn. J. Basic Med. Sci. 21, 270–283 (2021).

pubmed: 33052081 pmcid: 8112554

Nilsson, A. et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am. J. Gastroenterol. 90, 381–387 (1995).

pubmed: 7872274

Kim, D. H. Gut microbiota-mediated drug-antibiotic interactions. Drug Metab. Dispos. 43, 1581–1589 (2015).

pubmed: 25926432 doi: 10.1124/dmd.115.063867

Azad Khan, A. K., Guthrie, G., Johnston, H. H., Truelove, S. C. & Williamson, D. H. Tissue and bacterial splitting of sulphasalazine. Clin. Sci. (Lond.) 64, 349–354 (1983).

pubmed: 6129936 doi: 10.1042/cs0640349

Lee, H. J., Zhang, H., Orlovich, D. A. & Fawcett, J. P. The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica 42, 791–797 (2012).

pubmed: 22348441 doi: 10.3109/00498254.2012.660508

Crouwel, F., Buiter, H. J. C. & de Boer, N. K. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J. Crohns Colitis 15, 307–315 (2020).

pubmed: 32652007 pmcid: 7904070 doi: 10.1093/ecco-jcc/jjaa143

Savarino, V. et al. The appropriate use of proton-pump inhibitors. Minerva Med 109, 386–399 (2018).

pubmed: 29856192 doi: 10.23736/S0026-4806.18.05705-1

Graham, D. Y. & Tansel, A. Interchangeable use of proton pump inhibitors based on relative potency. Clin. Gastroenterol. Hepatol. 16, 800–808.e7 (2018).

pubmed: 28964908 doi: 10.1016/j.cgh.2017.09.033

Pinto-Sanchez, M. I., Yuan, Y., Bercik, P. & Moayyedi, P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst. Rev. 3, CD011194 (2017).

pubmed: 28271513

Forgacs, I. & Loganayagam, A. Overprescribing proton pump inhibitors. BMJ 336, 2–3 (2008).

pubmed: 18174564 pmcid: 2174763 doi: 10.1136/bmj.39406.449456.BE

Akram, F., Huang, Y., Lim, V., Huggan, P. J. & Merchant, R. A. Proton pump inhibitors: are we still prescribing them without valid indications? Australas. Med. J. 7, 465–470 (2014).

pubmed: 25550719 pmcid: 4259212 doi: 10.4066/AMJ.2014.2093

Eid, S. M. et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 49, 2561–2568 (2010).

pubmed: 21139293 doi: 10.2169/internalmedicine.49.4064

Bonder, M. J. et al. The influence of a short-term gluten-free diet on the human gut microbiome. Genome Med. 8, 45 (2016).

pubmed: 27102333 pmcid: 4841035 doi: 10.1186/s13073-016-0295-y

Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749–756 (2016).

pubmed: 26719299 doi: 10.1136/gutjnl-2015-310861

Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016).

pubmed: 26657899 doi: 10.1136/gutjnl-2015-310376

Freedberg, D. E. et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149, 883–885.e9 (2015).

pubmed: 26164495 doi: 10.1053/j.gastro.2015.06.043

Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).

pubmed: 29555994 pmcid: 6108420 doi: 10.1038/nature25979

Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015).

pubmed: 25337874 doi: 10.1038/nature13828

Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790–801 (2013).

pubmed: 24096337 pmcid: 4194195 doi: 10.1038/nri3535

Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047–2056 (2007).

pubmed: 17509031 doi: 10.1111/j.1572-0241.2007.01275.x

Baur, D. et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect. Dis. 17, 990–1001 (2017).

pubmed: 28629876 doi: 10.1016/S1473-3099(17)30325-0

Bajaj, J. S. et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am. J. Gastroenterol. 113, 1177–1186 (2018).

pubmed: 29872220 doi: 10.1038/s41395-018-0085-9

Stark, C. M., Susi, A., Emerick, J. & Nylund, C. M. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut 68, 62–69 (2019).

pubmed: 30377188 doi: 10.1136/gutjnl-2017-314971

Harirforoosh, S., Asghar, W. & Jamali, F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J. Pharm. Pharm. Sci. 16, 821–847 (2013).

pubmed: 24393558 doi: 10.18433/J3VW2F

Sostres, C., Gargallo, C. J. & Lanas, A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther. 15, S3 (2013).

pubmed: 24267289 pmcid: 3890944 doi: 10.1186/ar4175

Higuchi, K. et al. Present status and strategy of NSAIDs-induced small bowel injury. J. Gastroenterol. 44, 879–888 (2009).

pubmed: 19568687 doi: 10.1007/s00535-009-0102-2

Petruzzelli, M. et al. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin. Biochem. 40, 503–510 (2007).

pubmed: 17321514 doi: 10.1016/j.clinbiochem.2007.01.015

Boelsterli, U. A., Redinbo, M. R. & Saitta, K. S. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 131, 654–667 (2013).

pubmed: 23091168 doi: 10.1093/toxsci/kfs310

Yauw, S. T. K. et al. Microbial glucuronidase inhibition reduces severity of diclofenac-induced anastomotic leak in rats. Surg. Infect. (Larchmt.) 19, 417–423 (2018).

pubmed: 29624485 doi: 10.1089/sur.2017.245

Dashnyam, P. et al. beta-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut. Sci. Rep. 8, 16372 (2018).

pubmed: 30401818 pmcid: 6219552 doi: 10.1038/s41598-018-34678-z

Ervin, S. M. et al. Targeting regorafenib-induced toxicity through inhibition of gut microbial beta-glucuronidases. ACS Chem. Biol. 14, 2737–2744 (2019).

pubmed: 31663730 pmcid: 7254866 doi: 10.1021/acschembio.9b00663

Yang, B., Liu, H., Yang, J., Gupta, V. K. & Jiang, Y. New insights on bioactivities and biosynthesis of flavonoid glycosides. Trends Food Sci. Technol. 79, 116–124 (2018).

doi: 10.1016/j.tifs.2018.07.006

Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).

pubmed: 27126039 doi: 10.1126/science.aad3503

Dinan, T. G. & Cryan, J. F. The microbiome-gut-brain axis in health and disease. Gastroenterol. Clin. North Am. 46, 77–89 (2017).

pubmed: 28164854 doi: 10.1016/j.gtc.2016.09.007

LeWitt, P. A. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov. Disord. 30, 64–72 (2015).

pubmed: 25449210 doi: 10.1002/mds.26082

Marsot, A., Guilhaumou, R., Azulay, J. P. & Blin, O. Levodopa in Parkinson’s disease: a review of population pharmacokinetics/pharmacodynamics analysis. J. Pharm. Pharm. Sci. 20, 226–238 (2017).

pubmed: 28719359 doi: 10.18433/J30H04

van Kessel, S. P. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat. Commun. 10, 310 (2019).

pubmed: 30659181 pmcid: 6338741 doi: 10.1038/s41467-019-08294-y

Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, eaau6323 (2019).

pubmed: 31196984 doi: 10.1126/science.aau6323

Musil, V., Blankova, A. & Baca, V. A plea for an extension of the anatomical nomenclature: the locomotor system. Bosn. J. Basic Med. Sci. 18, 117–125 (2018).

pubmed: 29144891 pmcid: 5988530

Peretti, S. et al. The Yin-Yang pharmacomicrobiomics on treatment response in inflammatory arthritides: a narrative review. Genes (Basel) 14, 89 (2022).

pubmed: 36672830 doi: 10.3390/genes14010089

Zhao, S. et al. Drug repurposing by siderophore conjugation: synthesis and biological evaluation of siderophore-methotrexate conjugates as antibiotics. Angew. Chem. Int. Ed. Engl. 61, e202204139 (2022).

pubmed: 35802518 doi: 10.1002/anie.202204139

Romao, V. C., Lima, A., Bernardes, M., Canhao, H. & Fonseca, J. E. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol. Res. 60, 289–310 (2014).

pubmed: 25391609 doi: 10.1007/s12026-014-8564-6

Ramos-Romero, S. et al. Mechanistically different effects of fat and sugar on insulin resistance, hypertension, and gut microbiota in rats. Am. J. Physiol. Endocrinol. Metab. 314, E552–E563 (2018).

pubmed: 29351480 doi: 10.1152/ajpendo.00323.2017

Dunn, C. J. & Peters, D. H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49, 721–749 (1995).

pubmed: 7601013 doi: 10.2165/00003495-199549050-00007

Zhou, B. et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine 33, 122–133 (2018).

pubmed: 30049384 pmcid: 6085585 doi: 10.1016/j.ebiom.2018.06.029

Sayers, E., MacGregor, A. & Carding, S. R. Drug-microbiota interactions and treatment response: relevance to rheumatoid arthritis. AIMS Microbiol. 4, 642–654 (2018).

pubmed: 31294239 pmcid: 6613334 doi: 10.3934/microbiol.2018.4.642

Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 21, 895–905 (2015).

pubmed: 26214836 doi: 10.1038/nm.3914

Goodman, S. M., Cronstein, B. N. & Bykerk, V. P. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin. Exp. Rheumatol. 33, 272–278 (2015).

pubmed: 25536122

Halilova, K. I. et al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int. J. Rheumatol. 2012, 978396 (2012).

pubmed: 22844292 pmcid: 3400362 doi: 10.1155/2012/978396

Angelis-Stoforidis, P., Vajda, F. J. & Christophidis, N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol. 17, 313–320 (1999).

pubmed: 10410264

Dervieux, T. et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766–2774 (2004).

pubmed: 15457444 doi: 10.1002/art.20460

Clemens, J. Q. Infection and inflammation of the genitourinary tract. J. Urol. 208, 455 (2022).

pubmed: 35583402 doi: 10.1097/JU.0000000000002742

Choi, E., Buie, J., Camacho, J., Sharma, P. & de Riese, W. T. W. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res. Rep. Urol. 14, 87–108 (2022).

pubmed: 35386270 pmcid: 8977476

Terrisse, S. et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J. Immunother. Cancer 10, e004191 (2022).

pubmed: 35296557 pmcid: 8928383 doi: 10.1136/jitc-2021-004191

Daisley, B. A. et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat. Commun. 11, 4822 (2020).

pubmed: 32973149 pmcid: 7515896 doi: 10.1038/s41467-020-18649-5

Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G. & De Marzo, A. M. The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 15, 11–24 (2018).

pubmed: 29089606 doi: 10.1038/nrurol.2017.167

McCulloch, J. A. & Trinchieri, G. Gut bacteria enable prostate cancer growth. Science 374, 154–155 (2021).

pubmed: 34618567 doi: 10.1126/science.abl7070

Dickson, R. P., Erb-Downward, J. R., Martinez, F. J. & Huffnagle, G. B. The microbiome and the respiratory tract. Annu Rev. Physiol. 78, 481–504 (2016).

pubmed: 26527186 doi: 10.1146/annurev-physiol-021115-105238

Unger, S. A. & Bogaert, D. The respiratory microbiome and respiratory infections. J. Infect. 74, S84–S88 (2017).

pubmed: 28646967 doi: 10.1016/S0163-4453(17)30196-2

Man, W. H., de Steenhuijsen Piters, W. A. & Bogaert, D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15, 259–270 (2017).

pubmed: 28316330 pmcid: 7097736 doi: 10.1038/nrmicro.2017.14

Mi, J. et al. The research progress in immunotherapy of tuberculosis. Front. Cell Infect. Microbiol. 11, 763591 (2021).

pubmed: 34869066 pmcid: 8634162 doi: 10.3389/fcimb.2021.763591

Bermingham, W. H. et al. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs. Clin. Exp. Allergy 52, 375–386 (2022).

pubmed: 34939251 doi: 10.1111/cea.14084

Namasivayam, S. et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome 5, 71 (2017).

pubmed: 28683818 pmcid: 5501520 doi: 10.1186/s40168-017-0286-2

Naidoo, C. C. et al. The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. Lancet Respir. Med. 7, 892–906 (2019).

pubmed: 30910543 doi: 10.1016/S2213-2600(18)30501-0

Wipperman, M. F. et al. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci. Rep. 7, 10767 (2017).

pubmed: 28883399 pmcid: 5589918 doi: 10.1038/s41598-017-10346-6

Shen, Y. et al. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 12, 509–520 (2012).

pubmed: 22999859 pmcid: 3895402 doi: 10.1016/j.chom.2012.08.004

Larsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 151, 363–374 (2017).

pubmed: 28542929 pmcid: 5506432 doi: 10.1111/imm.12760

Wells, J. M. Immunomodulatory mechanisms of lactobacilli. Micro. Cell Fact. 10, S17 (2011).

doi: 10.1186/1475-2859-10-S1-S17

Scriba, T. J. et al. Differential recognition of mycobacterium tuberculosis-specific epitopes as a function of tuberculosis disease history. Am. J. Respir. Crit. Care Med. 196, 772–781 (2017).

pubmed: 28759253 pmcid: 5620682 doi: 10.1164/rccm.201706-1208OC

Hawn, T. R., Matheson, A. I., Maley, S. N. & Vandal, O. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol. Mol. Biol. Rev. 77, 608–627 (2013).

pubmed: 24296574 pmcid: 3973381 doi: 10.1128/MMBR.00032-13

Caballero-Flores, G., Pickard, J. M. & Nunez, G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat. Rev. Microbiol. 21, 347–360 (2023).

pubmed: 36539611 doi: 10.1038/s41579-022-00833-7

Gong, X. et al. The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: a review. Pharm. Res. 157, 104824 (2020).

doi: 10.1016/j.phrs.2020.104824

Hayase, E. & Jenq, R. R. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 13, 107 (2021).

pubmed: 34162429 pmcid: 8220726 doi: 10.1186/s13073-021-00923-w

Peng, Y. et al. Role of gut microbiota in travel-related acquisition of extended spectrum beta-lactamase-producing Enterobacteriaceae. J. Travel Med. 28, taab022 (2021).

pubmed: 33615366 doi: 10.1093/jtm/taab022

He, Z. et al. Gut microbiota-derived ursodeoxycholic acid from neonatal dairy calves improves intestinal homeostasis and colitis to attenuate extended-spectrum beta-lactamase-producing enteroaggregative Escherichia coli infection. Microbiome 10, 79 (2022).

pubmed: 35643532 pmcid: 9142728 doi: 10.1186/s40168-022-01269-0

Smet, A. et al. Broad-spectrum beta-lactamases among Enterobacteriaceae of animal origin: molecular aspects, mobility and impact on public health. FEMS Microbiol. Rev. 34, 295–316 (2010).

pubmed: 20030731 doi: 10.1111/j.1574-6976.2009.00198.x

Piewngam, P. et al. Composition of the intestinal microbiota in extended-spectrum beta-lactamase-producing Enterobacteriaceae carriers and non-carriers in Thailand. Int J. Antimicrob. Agents 53, 435–441 (2019).

pubmed: 30578963 doi: 10.1016/j.ijantimicag.2018.12.006

McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022).

pubmed: 35228752 pmcid: 10246505 doi: 10.1038/s41591-022-01698-2

Munier, A. L. et al. Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment. Int J. Antimicrob. Agents 46, 653–659 (2015).

pubmed: 26508586 doi: 10.1016/j.ijantimicag.2015.09.004

de Lastours, V. & Fantin, B. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiol. 10, 1241–1255 (2015).

pubmed: 26119580 doi: 10.2217/fmb.15.40

Klunemann, M. et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature 597, 533–538 (2021).

pubmed: 34497420 pmcid: 7614428 doi: 10.1038/s41586-021-03891-8

Abt, M. C., McKenney, P. T. & Pamer, E. G. Clostridium difficile colitis: pathogenesis and host defence. Nat. Rev. Microbiol. 14, 609–620 (2016).

pubmed: 27573580 pmcid: 5109054 doi: 10.1038/nrmicro.2016.108

O’Grady, K., Knight, D. R. & Riley, T. V. Antimicrobial resistance in Clostridioides difficile. Eur. J. Clin. Microbiol. Infect. Dis. 40, 2459–2478 (2021).

pubmed: 34427801 doi: 10.1007/s10096-021-04311-5

Gil, F. & Paredes-Sabja, D. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections. Future Microbiol. 11, 1179–1189 (2016).

pubmed: 27546386 doi: 10.2217/fmb-2016-0064

Liu, X., Chen, Y., Zhang, S. & Dong, L. Gut microbiota-mediated immunomodulation in tumor. J. Exp. Clin. Cancer Res. 40, 221 (2021).

pubmed: 34217349 pmcid: 8254267 doi: 10.1186/s13046-021-01983-x

Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28, 2344–2352 (2022).

pubmed: 36138151 doi: 10.1038/s41591-022-01965-2

Cheng, W. Y., Wu, C. Y. & Yu, J. The role of gut microbiota in cancer treatment: friend or foe? Gut 69, 1867–1876 (2020).

pubmed: 32759302 doi: 10.1136/gutjnl-2020-321153

Li, X., Zhang, S., Guo, G., Han, J. & Yu, J. Gut microbiome in modulating immune checkpoint inhibitors. EBioMedicine 82, 104163 (2022).

pubmed: 35841869 pmcid: 9297075 doi: 10.1016/j.ebiom.2022.104163

Lu, Y. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol. 15, 47 (2022).

pubmed: 35488243 pmcid: 9052532 doi: 10.1186/s13045-022-01273-9

Paone, P. & Cani, P. D. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut 69, 2232–2243 (2020).

pubmed: 32917747 doi: 10.1136/gutjnl-2020-322260

Takiishi, T., Fenero, C. I. M. & Camara, N. O. S. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers 5, e1373208 (2017).

pubmed: 28956703 pmcid: 5788425 doi: 10.1080/21688370.2017.1373208

Ianiro, G., Tilg, H. & Gasbarrini, A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65, 1906–1915 (2016).

pubmed: 27531828 doi: 10.1136/gutjnl-2016-312297

Becattini, S., Taur, Y. & Pamer, E. G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 22, 458–478 (2016).

pubmed: 27178527 pmcid: 4885777 doi: 10.1016/j.molmed.2016.04.003

Akbarali, H. I. & Dewey, W. L. Gastrointestinal motility, dysbiosis and opioid-induced tolerance: is there a link? Nat. Rev. Gastroenterol. Hepatol. 16, 323–324 (2019).

pubmed: 31024090 pmcid: 7045338 doi: 10.1038/s41575-019-0150-x

Kurz, A. & Sessler, D. I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63, 649–671 (2003).

pubmed: 12656645 doi: 10.2165/00003495-200363070-00003

Mora, A. L. et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am. J. Med. Sci. 343, 277–280 (2012).

pubmed: 21934595 doi: 10.1097/MAJ.0b013e31822f42eb

Zhuang, Y. P. et al. Gut microbiota interactions with antitumor immunity in colorectal cancer: from understanding to application. Biomed. Pharmacother. 165, 115040 (2023).

pubmed: 37364479 doi: 10.1016/j.biopha.2023.115040

Pezo, R. C., Wong, M. & Martin, A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. Ther. Adv. Gastroenterol. 12, 1756284819870911 (2019).

doi: 10.1177/1756284819870911

Bai, Z. et al. Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE(-/-) mice. Int. Immunopharmacol. 120, 110296 (2023).

pubmed: 37187127 doi: 10.1016/j.intimp.2023.110296

Kolodziejczyk, A. A., Zheng, D. & Elinav, E. Diet-microbiota interactions and personalized nutrition. Nat. Rev. Microbiol. 17, 742–753 (2019).

pubmed: 31541197 doi: 10.1038/s41579-019-0256-8

Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 35–56 (2019).

pubmed: 30262901 doi: 10.1038/s41575-018-0061-2

Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 16, 605–616 (2019).

pubmed: 31296969 doi: 10.1038/s41575-019-0173-3

Lim, H. et al. Artificial intelligence approaches to human-microbiome protein-protein interactions. Curr. Opin. Struct. Biol. 73, 102328 (2022).

pubmed: 35152186 doi: 10.1016/j.sbi.2022.102328

Cammarota, G. et al. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 635–648 (2020).

pubmed: 32647386 doi: 10.1038/s41575-020-0327-3

Vitetta, L., Coulson, S., Linnane, A. W. & Butt, H. The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics. Pathogens 2, 606–626 (2013).

pubmed: 25437335 pmcid: 4235701 doi: 10.3390/pathogens2040606

Bermudez-Brito, M., Plaza-Diaz, J., Munoz-Quezada, S., Gomez-Llorente, C. & Gil, A. Probiotic mechanisms of action. Ann. Nutr. Metab. 61, 160–174 (2012).

pubmed: 23037511 doi: 10.1159/000342079

Gupta, S., Allen-Vercoe, E. & Petrof, E. O. Fecal microbiota transplantation: in perspective. Ther. Adv. Gastroenterol. 9, 229–239 (2016).

doi: 10.1177/1756283X15607414

Ser, H. L., Letchumanan, V., Goh, B. H., Wong, S. H. & Lee, L. H. The use of fecal microbiome transplant in treating human diseases: too early for poop? Front. Microbiol. 12, 519836 (2021).

pubmed: 34054740 pmcid: 8155486 doi: 10.3389/fmicb.2021.519836

Khoruts, A. Fecal microbiota transplantation-early steps on a long journey ahead. Gut Microbes 8, 199–204 (2017).

pubmed: 28394706 pmcid: 5479406 doi: 10.1080/19490976.2017.1316447

van Nood, E., Speelman, P., Nieuwdorp, M. & Keller, J. Fecal microbiota transplantation: facts and controversies. Curr. Opin. Gastroenterol. 30, 34–39 (2014).

pubmed: 24241245 doi: 10.1097/MOG.0000000000000024

Borody, T. J. & Campbell, J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol. Clin. North Am. 41, 781–803 (2012).

pubmed: 23101687 doi: 10.1016/j.gtc.2012.08.008

Li, M. et al. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur. J. Pharm. 831, 52–59 (2018).

doi: 10.1016/j.ejphar.2018.05.003

Lin, D. M., Koskella, B. & Lin, H. C. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharm. Ther. 8, 162–173 (2017).

doi: 10.4292/wjgpt.v8.i3.162

Bourdin, G. et al. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Micro. Biotechnol. 7, 165–176 (2014).

doi: 10.1111/1751-7915.12113

Ackermann, H. W. The first phage electron micrographs. Bacteriophage 1, 225–227 (2011).

pubmed: 23050215 pmcid: 3448108 doi: 10.4161/bact.1.4.17280

Rakhuba, D. V., Kolomiets, E. I., Dey, E. S. & Novik, G. I. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol. J. Microbiol. 59, 145–155 (2010).

pubmed: 21033576 doi: 10.33073/pjm-2010-023

Motlagh, A. M., Bhattacharjee, A. S. & Goel, R. Biofilm control with natural and genetically-modified phages. World J. Microbiol Biotechnol. 32, 67 (2016).

pubmed: 26931607 doi: 10.1007/s11274-016-2009-4

Ramachandran, G. & Bikard, D. Editing the microbiome the CRISPR way. Philos. Trans. R. Soc. Lond. B Biol. Sci. 374, 20180103 (2019).

pubmed: 30905295 pmcid: 6452265 doi: 10.1098/rstb.2018.0103

Reyes, A., Wu, M., McNulty, N. P., Rohwer, F. L. & Gordon, J. I. Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc. Natl Acad. Sci. USA 110, 20236–20241 (2013).

pubmed: 24259713 pmcid: 3864308 doi: 10.1073/pnas.1319470110

Lusiak-Szelachowska, M., Weber-Dabrowska, B., Jonczyk-Matysiak, E., Wojciechowska, R. & Gorski, A. Bacteriophages in the gastrointestinal tract and their implications. Gut Pathog. 9, 44 (2017).

pubmed: 28811841 pmcid: 5553654 doi: 10.1186/s13099-017-0196-7

Divya Ganeshan, S. & Hosseinidoust, Z. Phage therapy with a focus on the human microbiota. Antibiotics (Basel) 8, 131 (2019).

pubmed: 31461990 doi: 10.3390/antibiotics8030131

Ren, Z. et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68, 1014–1023 (2019).

pubmed: 30045880 doi: 10.1136/gutjnl-2017-315084

Scott, A. J. et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut 68, 1624–1632 (2019).

pubmed: 31092590 doi: 10.1136/gutjnl-2019-318556

Rao, B. C. et al. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 19, 109–115 (2020).

pubmed: 32037278 doi: 10.1016/j.hbpd.2020.01.003

Kuntz, T. M. & Gilbert, J. A. Introducing the microbiome into precision medicine. Trends Pharm. Sci. 38, 81–91 (2017).

pubmed: 27814885 doi: 10.1016/j.tips.2016.10.001

Rizkallah, M. R., Saad, R. & Aziz, R. K. The Human Microbiome Project, personalized medicine and the birth of phar macomicrobiomics. Curr. Pharm. Pers. Med. 8, 182–193 (2010).

Drug-microbiota interactions: an emerging priority for precision medicine.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Qing Zhao (Q)

Yao Chen (Y)

Weihua Huang (W)

Honghao Zhou (H)

Wei Zhang (W)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH